Regorafenib in the treatment of metastatic colorectal cancer.

Regorafenib in the treatment of metastatic colorectal cancer.

Future Oncol. 2018 Mar 23;:

Authors: la Fouchardière C

Abstract
Regorafenib is an orally available multikinase inhibitor, currently approved in metastatic chemorefractory colorectal cancer patients. The results of two large randomized Phase III trials are available, providing significant results in overall and progression-free survival in this situation. Its use requires a special attention regarding patient selection, dosing schedule and management of adverse events. Identifying patients who will tolerate and have benefit from regorafenib is a challenge for clinicians. Therapeutic monitoring (especially cfDNA), predictive biomarkers and specific perfusion-based imaging techniques will may be result in optimizing regorafenib treatment.

PMID: 29569472 [PubMed - as supplied by publisher]

https://ift.tt/2G3Zuij